{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:39:03Z","timestamp":1783579143506,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Oligometastatic disease in prostate cancer (PCa) is a challenging clinical scenario encountered more frequently with the widespread adoption of PSMA-PET. SBRT aims to defer androgen deprivation and may deliver sustained biochemical failure (BF) free survival in selected patients. Little long-term data is currently available regarding the effectiveness of this approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective single institution study of PSMA-PET directed SBRT without initial ADT for oligo-metachronous PCa. Median dose\/fractionation was 24\u00a0Gy in 2# to bones and 30\u00a0Gy in 3# to lymph nodes. The primary endpoint was time to BF (PSA\u2009+\u20090.2 ug\/L above nadir). Secondary endpoints included time to ADT for relapse (i.e. palliative ADT), BF defined as PSA nadir\u2009+\u20092 ug\/L, toxicity, patterns of failure and survival. Patients were excluded if they received ADT with their SBRT, had short disease-free interval, or &gt;\u20093 metastases on PSMA-PET.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>103 patients treated from November-2014 to December-2019 were analysed from our prospective database. Median follow-up was 5 years. 64 patients were treated for nodal only disease, 35 bone only and 4 mixed. 15% were free of any BF at 5 years with median time to BF of 1.1 years. 32% (33\/103) of patients had further curative-intent radiation treatment following their first BF after SBRT, including subsequent SBRT. Eight patients underwent potentially curative treatment for their second or third relapse. Allowing for salvage treatment, 29\/103 (28%) were biochemically disease free at last follow up. At 5 years, 39% of patients had never received any ADT and 55% had not started ADT for relapse with a median time to ADT for relapse of 5.5 years. There were 2 grade 3 toxicities (rib fracture and lymphoedema), and no local failures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PSMA-PET guided SBRT for oligo-metachronous PCa recurrence in appropriately triaged patients results in excellent local control, low toxicity and over 50% ADT free at 5 years.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02302-8","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T15:01:56Z","timestamp":1690902116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Riche","family":"Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kneebone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Eade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"5","key":"2302_CR1","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bju.13397","volume":"117","author":"PJ van Leeuwen","year":"2016","unstructured":"van Leeuwen PJ, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117(5):732\u20139.","journal-title":"BJU Int"},{"issue":"8","key":"2302_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, et al. Prospective comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET\/CT in prostate Cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56(8):1185\u201390.","journal-title":"J Nucl Med"},{"key":"2302_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1186\/1471-2407-14-671","volume":"14","author":"K Decaestecker","year":"2014","unstructured":"Decaestecker K, et al. Surveillance or metastasis-directed therapy for OligoMetastatic prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer. 2014;14:671.","journal-title":"BMC Cancer"},{"issue":"6","key":"2302_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.euo.2018.04.017","volume":"1","author":"A Kneebone","year":"2018","unstructured":"Kneebone A, et al. Stereotactic body radiotherapy for oligometastatic prostate Cancer detected via prostate-specific membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2018;1(6):531\u20137.","journal-title":"Eur Urol Oncol"},{"key":"2302_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fonc.2015.00101","volume":"5","author":"G Azzam","year":"2015","unstructured":"Azzam G, et al. SBRT: an opportunity to improve quality of life for oligometastatic prostate Cancer. Front Oncol. 2015;5:101.","journal-title":"Front Oncol"},{"issue":"2","key":"2302_CR6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ijrobp.2016.01.032","volume":"95","author":"JL Muldermans","year":"2016","unstructured":"Muldermans JL, et al. Stereotactic body Radiation Therapy for oligometastatic prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;95(2):696\u2013702.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2302_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for oligometastatic prostate Cancer: the ORIOLE phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):650\u20139.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2302_CR8","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ijrobp.2019.08.029","volume":"105","author":"DE Spratt","year":"2019","unstructured":"Spratt DE, et al. Two years of Anti-Androgen Treatment increases other-cause Mortality in Men receiving early salvage Radiotherapy: a secondary analysis of the NRG Oncology\/RTOG 9601 Randomized Phase III Trial. Int J Radiation Oncology*Biology*Physics. 2019;105(3):680.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"5","key":"2302_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, et al. Surveillance or Metastasis-Directed therapy for oligometastatic prostate Cancer recurrence: a prospective, randomized, Multicenter Phase II Trial. J Clin oncology: official J Am Soc Clin Oncol. 2018;36(5):446\u201353.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"2302_CR10","doi-asserted-by":"crossref","unstructured":"H\u00f6lscher T et al. Local control after locally ablative, image-guided Radiotherapy of Oligometastases identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive prostate Cancer patients (OLI-P). Cancers (Basel), 2022. 14(9).","DOI":"10.3390\/cancers14092073"},{"key":"2302_CR11","doi-asserted-by":"crossref","unstructured":"Roberts MJ et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging, 2022.","DOI":"10.1007\/s00259-022-05756-2"},{"issue":"1116","key":"2302_CR12","doi-asserted-by":"publisher","first-page":"20200496","DOI":"10.1259\/bjr.20200496","volume":"93","author":"M Yan","year":"2020","unstructured":"Yan M, et al. Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence. Br J Radiol. 2020;93(1116):20200496.","journal-title":"Br J Radiol"},{"issue":"8","key":"2302_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, et al. Prospective comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET\/CT in prostate Cancer patients who have rising PSA after curative treatment and are being considered for targeted Therapy Journal of nuclear medicine: official publication. Soc Nuclear Med. 2015;56(8):1185\u201390.","journal-title":"Soc Nuclear Med"},{"issue":"6suppl","key":"2302_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1200\/JCO.2021.39.6_suppl.248","volume":"39","author":"C Fairmichael","year":"2021","unstructured":"Fairmichael C, et al. The stereotactic prostate radiotherapy (SPORT) trial: a randomized feasibility study comparing prostate SABR to prostate and pelvic nodal SABR. J Clin Oncol. 2021;39(6suppl):248\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2302_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.20.02438","volume":"39","author":"DE Spratt","year":"2021","unstructured":"Spratt DE, et al. Prostate Radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to Neoadjuvant ADT: an individual patient Meta-analysis. J Clin Oncol. 2021;39(2):136\u201344.","journal-title":"J Clin Oncol"},{"key":"2302_CR16","doi-asserted-by":"crossref","unstructured":"Spohn SKB et al. Risk factors for biochemical recurrence after PSMA-PET-Guided definitive Radiotherapy in patients with De Novo Lymph Node-Positive prostate Cancer. Front Oncol, 2022. 12.","DOI":"10.3389\/fonc.2022.898774"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02302-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02302-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02302-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T15:03:22Z","timestamp":1690902202000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02302-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2302"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02302-8","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"8 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data from Ethics Committee approved Clinical research Database, as approved by the NSLHD HREC with implicit patient consent via opt \u2013 out option. Reference Number:2019\/ETH08469.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}